论文部分内容阅读
Ustekinumab为一种用于治疗牛皮癣的新型单克隆抗体,是细胞因子IL-2和IL-3拮抗剂。这些细胞因子可激发1型辅助性T淋巴细胞反应,被认为能介导发生于牛皮癣中的异常免疫反应。强生Centocor公司在圣安东尼举行的美国皮肤病学会(AAD)会议上报告了由其开发的ustekinum-ab的第2项Ⅱ期
Ustekinumab is a novel monoclonal antibody for the treatment of psoriasis and is a cytokine IL-2 and IL-3 antagonist. These cytokines stimulate type 1 helper T lymphocyte responses and are thought to mediate an abnormal immune response that occurs in psoriasis. Johnson & Johnson Centocor company in San Antonio at the American Academy of Dermatology (AAD) meeting reported its development of ustekinum-ab of the second phase Ⅱ